| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Today, we stand as a larger, more mature company than ever before as we ramp revenues and product margins. We have a world class strategic partner, the necessary capital to execute on our strategic growth initiatives and several upcoming milestones that present significant opportunities to grow shareholder value.
As we look ahead, we are reiterating our fiscal year 2025 guidance, with product revenues expected to increase to between $8.0-$10.0 million, representing an increase of between 132%-190% when compared to product revenue of $3.5 million in fiscal year 2024, and expanded product gross margin of between 47%-51%, compared to product gross margin of 31% in fiscal year 2024.
Posted In: NMTC
